Chronic immune-related adverse events common after anti-PD-1 therapy for melanoma
Source: Healio, August 2023
Key takeaways:
- Nearly two-thirds of patients experienced acute immune-related adverse events.
- The most common persistent chronic adverse events included hypothyroid, arthritis dermatitis and adrenal insufficiency.
Chronic immune-associated adverse events appeared common after treatment with adjuvant anti-PD-1 therapy among patients with melanoma, according to study results published in JAMA Network Open.
The findings highlight the need for long-term monitoring and management of adverse events in this patient population, researchers concluded.